Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Sanofi and Regeneron’s once close relationship has ... refocus Sanofi since taking the helm – for example axing R&D in diabetes, once its cash-cow category, and cardiovascular – in order ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi.

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... which have the potential to treat more ...